Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis.
- Authors
- Glatt, Stephen J; Bousman, Chad; Wang, Richard S; Murthy, Kenton K; Rana, Brinda K; Lasky-Su, Jessica A; Zhu, Shao C; Zhang, Ruimin; Li, Jianhua; Zhang, Bo; Li, Jixiang; Lyons, Michael J; Faraone, Stephen V; Tsuang, Ming T
- Year
- 2007
- Journal
- Drug and alcohol dependence
- PMID
- 17416470
- DOI
- 10.1016/j.drugalcdep.2007.02.022
- PMCID
- PMC2012941
OPRM1, which codes for the mu-opioid receptor, is the most frequently studied candidate gene for opioid dependence. Despite numerous allelic association studies, no definitive conclusion has been reached regarding the role of OPRM1 polymorphisms in determining risk for opioid dependence. We attempted to resolve this by conducting a family-based association study and meta-analysis which may be more robust and powerful, respectively, than traditional case-control analyses. First, we genotyped three single nucleotide polymorphisms (SNPs) of OPRM1 in 1208 individuals from 473 Han Chinese families ascertained on the basis of having two or more siblings with DSM-IV-defined opioid dependence. The Val6Ala and Arg111His SNPs were detected, but with low minor allele frequencies (0.002 and 0.001, respectively). The Asn40Asp SNP was more informative (minor allele frequency: 0.419), but no significant evidence was observed for either a dominant (p=0.810) or additive (p=0.406) effect of this polymorphism on risk for opioid dependence. In addition, a meta-analysis of case-control studies of opioid dependence was performed, and found a similar lack of evidence for an association with the Asn40Asp SNP (p=0.859). Although a role of OPRM1 polymorphisms in determining risk for opioid dependence cannot be entirely discounted, a major contribution of the Asn40Asp polymorphism seems unlikely. Further analysis is warranted in samples from specific ancestral groups. In addition, it is critical that other OPRM1 variants, including all haplotype-tagging and amino-acid-coding SNPs, be tested for an influence on risk for opioid dependence, since the Asn40Asp polymorphism is only one of several hundred known mutations in the gene.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Allele frequency and genotype distribution of the opioid receptor ΞΌ-1 (OPRM1) A118G polymorphism in the Western Saudi population. | Bagher AM et al. | β | 2023 | β |
| Mu opioid receptor gene variant modulates subjective response to smoked cannabis. | Bourgault Z et al. | β | 2022 | β |
| Tackling the opioid crisis: Novel mechanisms and clinical perspectives. | Leduc-Pessah H et al. | β | 2022 | β |
| An integrative analysis of genome-wide association study and regulatory SNP annotation datasets identified candidate genes for bipolar disorder. | Qi X et al. | β | 2020 | β |
| Genome-Wide Association Study of Opioid Cessation. | Cox JW et al. | β | 2020 | β |
| Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact of <i>OPRM1</i> A/G Polymorphism on Its Effectiveness. | Verholleman A et al. | β | 2020 | β |
| Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism. | Cornett EM et al. | β | 2020 | β |
| An update on the safety of prescribing opioids in pediatrics. | Parikh JM et al. | β | 2019 | β |
| A review of opioid addiction genetics. | Crist RC et al. | β | 2019 | β |
| Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. | Schwantes-An TH et al. | β | 2016 | β |
| Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1. | Hancock DB et al. | β | 2015 | β |
| Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. | Nelson EC et al. | β | 2014 | β |
| Higher frequency of C.3435 of the ABCB1 gene in patients with tramadol dependence disorder. | Enabah D et al. | β | 2014 | β |
| Mu opioid receptor gene: new point mutations in opioid addicts. | Dinarvand A et al. | β | 2014 | β |
| Pharmacogenetics of OPRM1. | Crist RC et al. | β | 2014 | β |
| Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? | Mura E et al. | β | 2013 | β |
| Low frequency genetic variants in the ΞΌ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine. | Clarke TK et al. | β | 2013 | β |
| OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. | Haerian BS et al. | β | 2013 | β |
| Shared and unique genetic contributions to attention deficit/hyperactivity disorder and substance use disorders: a pilot study of six candidate genes. | Carpentier PJ et al. | β | 2013 | β |
| Common and specific liability to addiction: approaches to association studies of opioid addiction. | Nielsen DA et al. | β | 2012 | β |
| Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. | Kreek MJ et al. | β | 2012 | β |
| Pharmacogenetically driven treatments for alcoholism: are we there yet? | Arias AJ et al. | β | 2012 | β |
| The genetics of addiction-a translational perspective. | Agrawal A et al. | β | 2012 | β |
| The genetics of the opioid system and specific drug addictions. | Levran O et al. | β | 2012 | β |
| Haplotype block structure of the genomic region of the mu opioid receptor gene. | Levran O et al. | β | 2011 | β |
| No evidence of association between 118A>G OPRM1 polymorphism and heroin dependence in a large Bulgarian case-control sample. | Nikolov MA et al. | β | 2011 | β |
| Pharmacogenomics of the human Β΅-opioid receptor. | Kasai S et al. | β | 2011 | β |
| The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. | Soyka M et al. | β | 2011 | β |
| Genetics of drug dependence. | Gelernter J et al. | β | 2010 | β |
| OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. | Mague SD et al. | β | 2010 | β |
| Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. | Yuferov V et al. | β | 2010 | β |
| Genetic association studies of methamphetamine use disorders: A systematic review and synthesis. | Bousman CA et al. | β | 2009 | β |
| Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. | Coller JK et al. | β | 2009 | β |
| Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. | Mague SD et al. | β | 2009 | β |
| Candidate gene polymorphisms predicting individual sensitivity to opioids. | Kasai S et al. | β | 2008 | β |
| Endogenous opiates and behavior: 2007. | Bodnar RJ | β | 2008 | β |
| Genetic susceptibility to heroin addiction: a candidate gene association study. | Levran O et al. | β | 2008 | β |
| Genome-wide linkage analysis of heroin dependence in Han Chinese: results from Wave Two of a multi-stage study. | Glatt SJ et al. | β | 2008 | β |